Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off

Teva to sell API business to focus on growth

Published Feb 12, 2024 07:45AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
TEVA
+2.66%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

TEL AVIV - Teva Pharmaceutical Industries (NYSE:TEVA) Ltd. (NYSE and TASE: TEVA), a global pharmaceutical leader, announced its intention to divest its active-pharmaceutical ingredient (API) division, TAPI. The move is part of Teva's "Pivot to Growth" strategy, which aims to concentrate on core business areas and reallocate capital towards innovation and growth engines. The divestiture is expected to enhance TAPI's position as a global leader in the API market, which is valued at $85B.

TAPI, recognized as a leader in the small-molecule API industry, employs roughly 4,300 people worldwide. The divestiture is anticipated to allow Teva to better focus on distinct markets and drive growth through its leading product offerings. It is also expected to provide additional value to Teva’s shareholders and stakeholders by enabling Teva to invest more in its growth drivers and accelerate its innovative and biosimilar pipeline.

Richard Francis, President and CEO of Teva, stated that the divestiture will increase focus on Teva's core business and position its generics portfolio for future growth. R. Ananth, CEO of TAPI, expressed that operating independently would allow TAPI to capture more growth opportunities and continue to support generics and innovators globally, including Teva.

The completion of the divestiture is targeted for the first half of 2025, contingent upon reaching agreeable transaction terms with a prospective buyer, satisfying closing conditions, and obtaining approval from Teva’s Board of Directors. However, Teva notes that there is no certainty regarding the final timing or structure of the divestiture, or if it will occur at all.

TAPI serves over 1,000 clients worldwide, offering a portfolio of 350 products across various therapeutic areas. Its operations are crucial for delivering high-quality medications, supported by a sophisticated supply chain and a commitment to regulatory and quality excellence.

Teva, with a history of over 120 years, continues to push scientific innovation and deliver quality medicines. The company employs around 37,000 people across 58 markets, dedicated to improving the health outcomes of millions of patients.

This news article is based on a press release statement from Teva Pharmaceutical Industries Limited.

InvestingPro Insights

In light of Teva Pharmaceutical Industries Ltd.'s strategic move to divest its API division, TAPI, current and potential investors might find the following InvestingPro metrics and tips valuable. With a market capitalization of $13.19 billion, Teva is positioned as a prominent player in the pharmaceutical industry. Despite not being profitable over the last twelve months, analysts are optimistic about Teva's future, expecting net income growth this year and predicting the company will return to profitability. This is underscored by the fact that three analysts have revised their earnings upwards for the upcoming period.

InvestingPro data highlights that Teva has been trading near its 52-week high, with the price at 96.07% of this peak. The company has also experienced a strong return over the last three months, with a 36.71% price total return, reflecting a large price uptick over the last six months. These metrics may signal investor confidence in Teva's growth trajectory and restructuring efforts.

For those looking to dive deeper into Teva's financial health and future prospects, InvestingPro offers additional insights. Subscribers can access a wealth of InvestingPro Tips, including Teva's high shareholder yield and more comprehensive analysis on the company’s financials. Currently, there are 9 additional tips available for Teva on InvestingPro, which can be accessed with a subscription now on a special New Year sale with a discount of up to 50%. Use coupon code SFY24 to get an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 to get an additional 10% off a 1-year InvestingPro+ subscription.

As Teva streamlines its operations and focuses on its core business, these insights can help investors make informed decisions about their investments in the pharmaceutical sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Teva to sell API business to focus on growth
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email